Suspension of trading

NeuBase Therapeutics, Inc. Share Price

O7P

US64132K2015

Biotechnology & Medical Research

Market Closed - Deutsche Boerse AG 07:03:16 13/05/2024 BST			5-day change	1st Jan Change
0.3406 ^EUR	-0.58%		-.--%	-

07/01/25	Neubase Therapeutics, Inc. Announces Resignation of Todd P. Branning as Chief Financial Officer	CI
07/01/25	Neubase Therapeutics, Inc. Announces Resignation of Todd P. Branning as Interim Chief Executive Officer	CI

Valuation: NeuBase Therapeutics, Inc.

Market Cap	1.28M 1.13M 1.06M 963K 1.82M 123M 1.83M 12.76M 4.96M 62.8M 4.8M 4.69M 202M	P/E 2023 *	-	P/E 2024 *	-
Enterprise Value	1.28M 1.13M 1.06M 963K 1.82M 123M 1.83M 12.76M 4.96M 62.8M 4.8M 4.69M 202M	EV / Sales 2023 *	-	EV / Sales 2024 *	-
Free-Float	86.62%	Yield 2023 *	-	Yield 2024 *	-

* Estimated data More valuation ratios

Latest news: NeuBase Therapeutics, Inc.

07/01/25	Neubase Therapeutics, Inc. Announces Resignation of Todd P. Branning as Chief Financial Officer	CI
07/01/25	Neubase Therapeutics, Inc. Announces Resignation of Todd P. Branning as Interim Chief Executive Officer	CI
27/06/24	NeuBase Therapeutics, Inc. Announces Board Resignations	CI
28/05/24	NeuBase Therapeutics, Inc. announced that it has received $0.000001 million in funding	CI

More news

Managers and Directors: NeuBase Therapeutics, Inc.

Manager	Title	Age	Since
Ron Sarkar PRN	Corporate Officer/Principal	-	31/10/2021

Director	Title	Age	Since
Todd Branning BRD	Director/Board Member	56	03/01/2025

More insiders

Other Biotechnology & Medical Research

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
NEUBASE THERAPEUTICS, INC.	-0.58%	-.--%	-.--%	-50.64%	1.39M
WUXI APPTEC CO., LTD.	+4.16%	+3.42%	+49.37%	+94.17%	74.31B
ARGENX SE	+2.76%	-1.16%	+23.05%	+83.03%	56.95B
LONZA GROUP AG	+0.24%	-1.37%	+4.08%	+37.22%	48.3B
REVOLUTION MEDICINES, INC.	-3.76%	-0.93%	+327.90%	+691.25%	44.51B
IQVIA HOLDINGS INC.	-2.30%	-4.06%	+25.82%	+31.42%	43.8B
BEONE MEDICINES AG	+0.31%	-1.15%	+5.50%	+112.56%	41.12B
CELLTRION, INC.	-0.11%	+2.30%	+9.19%	+58.68%	31.07B
WUXI BIOLOGICS (CAYMAN) INC.	+4.51%	+8.43%	+37.27%	+34.97%	28.97B
BIONTECH SE	-1.96%	-3.38%	-9.25%	-12.85%	24.53B
Average	+0.33%	-0.60%	+47.29%	+107.98%	39.36B
Weighted average by Cap.	+0.77%	-0.50%	+56.58%	+134.21%

See all sector performances

NeuBase Therapeutics, Inc. is a United States-based preclinical-stage biotechnology company. It is developing a modular peptide-nucleic acid (PNA) antisense oligo (PATrOL) platform to address genetic diseases, with a single, cohesive approach. The Companyâ€™s programs are NT-0100 in HD, NT-0200 in myotonic dystrophy type 1 (DM1) and NT-0300 in KRAS-driven cancers. The NT-0100 program is a PATrOL-enabled therapeutic program being developed to target the mutant expansion in the HD DNA or RNA. The NT-0200 program is a PATrOL-enabled therapeutic program being developed to target the mutant expansion in the DM1 disease RNA. The NT-0300 program is a PATrOL-enabled therapeutic program being developed to target the mutated KRAS gene. It uses its platform to address diseases which have a genetic source, with an initial focus on gene silencing in DM1, Huntingtonâ€™s disease (HD), and oncology and in gene editing applications.

Employees

Sector

Biotechnology & Medical Research

More about the company